#USA #Pasadena #Alexandria Real Estate #depression treatment #FNIH

Alexandria Real Estate Equities Partners with FNIH for a Revolutionary Depression Initiative

In a landmark announcement on July 29, 2026, Alexandria Real Estate Equities, Inc. (NYSE: ARE) has revealed a pivotal collaboration with the Foundation for the National Institutes of Health (FNIH). This partnership marks a significant milestone in the quest to advance precision medicine in the treatment of major depressive disorder (MDD). The initiative, known as the Multi-Modal Assessment and Phenotyping in Depression (MAP-D), has reached its critical design phase, laying the groundwork for an innovative clinical study.

Major depressive disorder is a condition that affects over 21 million adults in the United States annually, with a troubling one-third of these individuals suffering from treatment-resistant depression. Dr. Lynne Zydowsky, chief of science at Alexandria Real Estate Equities, expressed that the current diagnostic methods for depression have been overly reliant on symptom observation, failing to account for the biological variances that exist between patients.

By focusing on precision medicine, the MAP-D initiative intends to explore biological markers associated with depression, which will enable the development of personalized treatment plans. The goal is to produce tailored therapies that can significantly improve patient outcomes—a much-needed advance in a field where the one-size-fits-all approach has often been inadequate.

The inception of this initiative was supported by Alexandria's strategic contribution, which allowed for the establishment of this public-private partnership. Alexandria has garnered recognition for its leadership in the life sciences sector and was awarded the Charles A. Sanders, MD, Partnership Award by the FNIH in 2025. This accolade acknowledged Alexandria's exceptional role in accelerating biomedical innovations.

The MAP-D aims to compile one of the most extensive datasets on depression, with a research scope projected to exceed $70 million. The first phase includes a three-year pilot study, commencing with an initial funding of $22 million. Through the use of advanced artificial intelligence, researchers will analyze the connections between biological indicators and patient results, aiming to define subtypes of depression. This newfound classification system will facilitate more precise therapy selection, which could potentially enhance treatment effectiveness and overall patient care.

In addition to improving individual treatments, the results of the MAP-D initiative are designed to be accessible to researchers across the globe, fostering transparency and collaboration. This open-data approach stands to enhance scientific discovery and may extend its precision medicine framework beyond depression to other serious mental illnesses.

As the healthcare landscape evolves, the push for personalized medicine becomes increasingly vital. The collaboration between Alexandria Real Estate Equities and the Foundation for the National Institutes of Health represents a transformative leap toward understanding and treating depression in a more scientifically rigorous and comprehensive manner.

For those interested in following the developments of the MAP-D initiative and the partners involved, more information can be found at fnih.org/our-programs/multi-modal-assessment-phenotyping-depression.

About Alexandria Real Estate Equities, Inc.

Founded in 1994, Alexandria Real Estate Equities, Inc. (NYSE: ARE) is a leader in life sciences real estate. With a commitment to making a positive impact, the company specializes in developing collaborative ecosystems in key innovation clusters. Alexandria manages prime properties across several major U.S. cities including Boston, the San Francisco Bay Area, and New York City, solidifying its position as a cornerstone in the life sciences sector.

For further inquiries, please contact:
Sara Cohen
Assistant Vice President – Capital Markets
Corporate Operations, (646) 799-2617
[Email Address]